Psilos II

Psilos Group Managers, LLC is a venture capital firm founded in 1998 and headquartered in New York, with additional offices in California, New Mexico, and Massachusetts. The firm specializes in investments in mid to later stage healthcare companies, focusing on healthcare services, healthcare information technology, and medical technology, including devices and diagnostics. Psilos typically invests between $8 million and $15 million per deal, with a total investment expectation of $20 million to $25 million over the life of an investment. The firm aims to take lead or co-lead positions in financing rounds, primarily targeting the second or third rounds of institutional investment. Psilos actively seeks to partner with experienced management teams and aims to support companies that have the potential to transform the healthcare sector through innovative services and technologies. By leveraging its extensive network of industry relationships, Psilos strives to enhance the strategic development of its portfolio companies, fostering their growth and facilitating successful liquidity events.

David (Dave) Eichler

Managing Member

Stephen M. Krupa

Managing Partner & Chief Executive Officer

Matt Levin

Managing Partner

Joseph R. Riley

Chief Administrative Office and Managing Partner

Albert S. Waxman

Founder and Managing Partner

Past deals in New Mexico

VeraLight

Series C in 2008
VeraLight is a medical device company that was established in October 2004 to focus on a comprehensive approach to non-invasive type 2 diabetes and pre-diabetes screening with the proprietary SCOUT DS® system. Their mission is to help stem the tide of the worldwide diabetes epidemic by driving early diabetes detection, thus enabling initiation of therapies that can prevent diabetes or reduce its complications. The company develops and acquires intellectual property, products, and services that contribute to this mission.

VeraLight

Series B in 2006
VeraLight is a medical device company that was established in October 2004 to focus on a comprehensive approach to non-invasive type 2 diabetes and pre-diabetes screening with the proprietary SCOUT DS® system. Their mission is to help stem the tide of the worldwide diabetes epidemic by driving early diabetes detection, thus enabling initiation of therapies that can prevent diabetes or reduce its complications. The company develops and acquires intellectual property, products, and services that contribute to this mission.